Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as meropenem (active comparator), Merrem
meropenem · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Meropenem |
| 2 | ACTIVE_COMPARATOR | Imipenem-cilastatin |
| Name | Type | Description |
|---|---|---|
| Meropenem | DRUG | Intravenous |
| Imipenem-cilastatin | DRUG | Intravenous |
Inclusion Criteria: * Subjects are hospitalized males and females, aged 13 years or older, with clinical evidence of complicated skin and skin structure bacterial infection with material suitable for culture from 1 primary site of infections * Within 72 hours before enrollment or at the time of enr...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
Meropenem is studied for the treatment of skin infections, including complicated skin and skin structure infections such as abscesses and cellulitis. It is an infectious disease therapy developed by Pfizer, Inc. (PFE) and has been evaluated in a Phase 3 trial in patients aged 13 years and older.
Meropenem is developed by Pfizer, Inc., which trades under the ticker PFE. The company sponsored the Phase 3 clinical program evaluating meropenem in complicated skin and skin structure infections.
Meropenem is in Phase 3 development for skin infections. The Phase 3 trial has been completed, and no active trials are currently listed. Meropenem is an investigational therapy in this program and is not described as approved for this indication.
Meropenem has been evaluated in one completed Phase 3 trial, NCT00619710, titled Complicated Skin and Skin Structure Infections. The trial enrolled 1,000 participants aged 13 years and older, was randomized, double-blind, and used an active-controlled design.
Yes. Meropenem is also referred to as meropenem (active comparator) in the context of the Phase 3 trial NCT00619710, where it was used as the active comparator arm. Both names refer to the same small molecule developed by Pfizer, Inc. (PFE).